Lung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive, and difficult-to-treat tumor. It is classified as a neuroendocrine subtype of large cell lung carcinoma (LCLC) belonging to the non-small cell lung cancer (NSCLC) group, but it is also included in the neuroendocrine tumor (NET) group. Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I–II–III), surgery is recommended but does not seem to be sufficient. Platinum-based adjuvant chemotherapy may be useful while the role of neoadjuvant chemotherapy is still not well defined. In patients with advanced L-LCNEC, the chemotherapy regimens used in SCLC still remain the standard of treatment, but results are not satisfactory. Due to their peculiar clinical and biological features and the lack of literature data, there is an emerging need for a consensus on the best treatment strategy for L-LCNEC and for the identification of new therapeutic options. In this review, we will discuss the key aspects of L-LCNEC management with the aim to clarify the most controversial issues.

Treatment of lung large cell neuroendocrine carcinoma / G. Lo Russo, S. Pusceddu, C. Proto, M. Macerelli, D. Signorelli, M. Vitali, M. Ganzinelli, R. Gallucci, N. Zilembo, M. Platania, R. Buzzoni, F. de Braud, M.C. Garassino. - In: TUMOR BIOLOGY. - ISSN 1010-4283. - 37:6(2016 Jun), pp. 7047-7057.

Treatment of lung large cell neuroendocrine carcinoma

S. Pusceddu
Secondo
;
F. de Braud
Penultimo
;
2016-06

Abstract

Lung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive, and difficult-to-treat tumor. It is classified as a neuroendocrine subtype of large cell lung carcinoma (LCLC) belonging to the non-small cell lung cancer (NSCLC) group, but it is also included in the neuroendocrine tumor (NET) group. Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I–II–III), surgery is recommended but does not seem to be sufficient. Platinum-based adjuvant chemotherapy may be useful while the role of neoadjuvant chemotherapy is still not well defined. In patients with advanced L-LCNEC, the chemotherapy regimens used in SCLC still remain the standard of treatment, but results are not satisfactory. Due to their peculiar clinical and biological features and the lack of literature data, there is an emerging need for a consensus on the best treatment strategy for L-LCNEC and for the identification of new therapeutic options. In this review, we will discuss the key aspects of L-LCNEC management with the aim to clarify the most controversial issues.
Chemotherapy; Large cell neuroendocrine carcinoma; Lung neuroendocrine tumor; Treatment options; Cancer Research
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
art%3A10.1007%2Fs13277-016-5003-4.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 401.58 kB
Formato Adobe PDF
401.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/442408
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 41
social impact